Moreover, knockdown of BTRC could increase ATGL levels, inhibit TAG accumulation, and ameliorate hepatic steatosis, suggesting the potential of targeting BTRC for the treatment of NAFLD. This evidence concerns the gene PNPLA2 and metabolic dysfunction-associated steatotic liver disease.